Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Healthy Community Project

- PMLiVE

Sanofi settles Lemtrada dispute with Genzyme investors for $315m

The MS drug has been in decline amid increased market competition

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Research Partnership

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

- PMLiVE

Dupixent gains can’t keep Sanofi on a growth track

Reports fall in Q3 sales despite growth of immunology drug

- PMLiVE

Sanofi/Regeneron wins another EU approval for Dupixent

Becomes first biologic approved in EU for CRSwNP indication

AstraZeneca AZ

AZ reports growth again in Q3, driven by oncology and China sales

Company has also returned to growth in Europe

- PMLiVE

Merck KGaA launches €13m seed fund for Chinese startups

Company also officially opens innovation hub in Shanghai

- PMLiVE

J&J expands Darzalex use with another first-line FDA approval

Could help defend myeloma franchise against rival Sanofi

- PMLiVE

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

Sets up regulatory filings and possible approval next year

Sanofi reception

Sanofi exits Zynquista alliance with Lexicon

Will pay $260m to end collaboration

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

NHS leaders warn of no-deal Brexit flu vaccine delays

Follows prior delay in production of the vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links